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ABSTRACT 
Lomeguatrib or Patrin-2 has been formulated to work in combination with 
Temozolomide. It does so by blocking the action of ATase (MGMT), which 
repairs specific kinds of DNA damage and is particularly responsible for 
resistance to anti-cancer treatments. Patrin-2 acts as a pseudosubstrate inactivator 
of MGMT. It thus, helps Temozolomide proceed with it’s designed action, which 
now cannot be stopped by neither MGMT nor MMR. The degradation behaviour 
of Patrin-2 was studied by subjecting it to various stress conditions. A validated 
stability indicating high-performance liquid chromatography method was 
established for the analysis of the drug in the presence of its various degradation 
products. An acceptable separation of the drug and its degradation products was 
achieved on a C18 reverse phased column (Symmetry 300) using a mobile phase 
that consisted of 10mM TBAA, 10mM SDS and 25mM citric acid in 35:65 
acetonitrile and HPLC grade water. 285nm was determined as the wavelength 
max for Patrin-2, however, three wavelengths (240nm, 254nm, 285nm) were 
selected for the study, so as to make sure, no degradation product of Patrin-2 goes 
undetected. The method was validated for linearity, accuracy, precision, 
selectivity, specificity and robustness. It proved to be linear over the range of 
concentration of 1-5mg/dL (n=2) with a correlation coefficient of 0.999. The 
RSD was found to be as low as 0.029 and 0.233 for it’s repeatability and 
reproducibility. The drug was found to be unstable when exposed to 0.4M of 
30%H2O2. It was highly unstable in acidic condition, undergoing complete 
degradation in less than an hour when subjected to 0.1M H2SO4. It underwent 
high degradation when subjected to photolytic stress (UV radiations) or thermal 
stress (incubated at 50
o
C and 80
o
C). The drug was solubilised in n-
methylpyrrolidone, one of the components used to tabulate it, but the results 
could not be confirmed, as no degradation product could be seen, but a change in 
shape of the peak was observed. 
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1.1 Cancer: Glioma and treatments 
 Cancer is the uncontrolled growth of normal cells and their spread to other parts 
of the body (Trent et al., 2002). Various types of cancer are diagnosed: cervical, 
lung, brain, skin, blood and many others as cancer can affect almost any type of 
body tissue. The abnormal cancer cells invade the surrounding normal tissue and 
can thus spread on to distant sites in the body (Sawyer et al., 2006). Many cancers 
can be prevented by taking precautions when exposed to known common risk 
factors, such as tobacco smoke, radioactivity, UV radiations, as indicated by 
World Health Organisation (Kleihues et al., 2002). In addition, a significant 
proportion of cancers can be cured, by surgery, radiotherapy or chemotherapy, 
especially if they are detected early. 
 
1.1.1 Gliomas 
A glioma is the most widely affecting form of brain cancer. It is a medical term 
for a tumour that originates in the brain or spine. The name glioma is derived 
from the fact that it starts from glial cells  (Chang et al., 2005).  
Tumours can develop in any part of the brain or its nerves and covering tissues. 
The two major types of brain tumour are primary and secondary. Primary brain 
tumours start in the brain. Secondary brain tumours start in another part of the 
body, then spread to the brain (Maher et al., 2001). A glioma is a primary brain 
tumour, accounting for 45% of cancers that begin in brain cells. 
The three main types of glioma include: astrocytoma, ependymoma, and 
oligodendroglioma. Each of these types can be assigned a grade, either low grade 
or high grade, with high grade being more malignant and aggressive (Bobola et 
al., 2004). 
Astrocytomas are named for the cells where they originate, the astrocytes. These 
tumours can either show clear borders between normal brain tissue and the 
tumour (called focal) or no clear border (called diffuse). Focal astrocytomas are 
most common in children and are not often found in adults. 
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Ependymomas begin in cells called ependymal cells that are found lining certain 
areas of the brain and spinal cord. These cells help repair damaged nerve tissue. 
They usually occur in children and young adults. 
Oligodendrogliomas form in oligodendrocyte cells, which produce a fatty 
substance called myelin that protects the nerve. More common in adults, these 
tumours may move to other parts of the brain or spinal cord. 
1.1.2 Treatment: Chemotherapy 
  Chemotherapy is the major treatment technique for cancer. Various drugs have 
been formulated for the cancer treatment which works by altering or damaging 
the DNA or RNA. They treat cancer, if used at early stages, but again have their 
own side effects. These could sometimes be killing the healthy cells or sometimes 
altering the DNA to bring about a mutation. Likewise, the cancer cells regenerate 
after chemotherapy by activating their DNA repair system and so cancer 
resurfaces. At such times, damaging the DNA to an extent that their repair system 
is not reactivated is like boon and not a side effect. Scientists have not only been 
working on formulating drugs which could be given in combination with the 
chemotherapy drugs to cure or reverse or simply erase the adverse effects but also 
been working on those that can  bring about a damage that would make the cure 
permanent. 
Temozolomide 
Temozolomide, a triazene compound, has been successfully used for the 
treatment of cancer for the past few years. Temozolomide is an alkylating agent 
that mediates its cytotoxic effects via O
6
-methylguanine (O
6
-meG) adducts in 
DNA and their recognition and processing by the postreplication mismatch repair 
system (MMR). (Kang et al., 1992).     O
6
-meG adducts can be repaired by the 
DNA repair protein O
6
-alkylguanine-DNA-alkyltransferase (MGMT), which 
therefore constitutes a major resistance mechanism to the drug. Unlike many 
other chemotherapy drugs, it can reach the brain via the bloodstream. It slows or 
stops the growth of cancer cells, which causes them to die. The epigenetic 
silencing of the MGMT (O
6
-methylguanine–DNA methyltransferase) DNA-repair 
gene by promoter methylation compromises DNA repair and has been associated 
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with longer survival in patients with glioblastoma who receive alkylating agents 
(Westphal et al., 2003; Stupp et al., 2005).  
 However, resistance to Temozolomide can also be mediated by loss of MMR, 
which is frequently mediated by methylation of thehMLH1 gene promoter. A 
summary of this can be seen in Figure 1.1. 
 
Figure 1.1 Figure showing resistance to the effect of Temozolomide by the 
MGMT, MMR and BER repair systems. Adapted from Kim, H et al, 2001. Pg 
463 
1.2 Lomeguatrib 
Lomeguatrib or Patrin-2 is a drug recently formulated by the Paterson Cancer 
Institute, Manchester at the University of Manchester. The chemical structure of 
this drug is shown in Fig.1. It works by causing lethal DNA damage. If cancer 
cells are able to repair damaged DNA they can often survive the effects of 
treatment, so scientists aimed to develop drugs to inhibit DNA repair, in order to 
make Temozolomide chemotherapy more effective (Turriziani et al., 2006). 
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Patrin-2 blocks the action of a molecule called ATase, which repairs specific 
kinds of DNA damage and is particularly important in resistance to anti-cancer 
treatments (Khan et al., 2008). Methylation of hMLH1 can be reversed by 
treatment of cells with 5-aza-2′-deoxycytidine, while the MGMT 
pseudosubstrate O
6
-(4-bromothenyl) guanine (Patrin-2) can deplete MGMT 
activity. Using a drug-resistant cell line which expresses MGMT and has 
methylated hMLH1, it can be observed that while either of these treatments can 
individually sensitize cells to Temozolomide (Verbeek et al., 2008) the combined 
treatment leads to substantially greater sensitization. The increased sensitization 
is not observed in matched MMR proficient cells. 
 
Figure 1.2 Structure of Lomeguatrib. 
 
The biological effects of triazene compounds and cell resistance to them depend 
on at least three DNA repair systems, (a) O
6
-alkylguanine-DNA-alkyltransferase, 
called also methyl-guanine methyl-transferase (MGMT); (b) mismatch repair 
(MMR), and (c) base excision repair (BER). (Marchesi et al., 2007) 
 MGMT is a small enzyme-like protein which is responsible for removing small 
alkyl adducts from the O
6
 position of DNA guanine through a stoichiometric and 
auto-inactivating reaction (Verbeek et al., 2008). This reaction consists in a 
covalent transfer of the alkyl group from the alkylated site in DNA to an internal 
cysteine residue of MGMT protein. Normal and tumour cell start resisting 
triazenes due to high levels of MGMT. Pre-treatment with MGMT inhibitors such 
as  O
6
-benzylguanine or O
6
-(4-bromotenyl)guanine (Lomeguatrib) is therefore 
recommended as it results in an increase in the activity of triazenes against target 
cells expressing high MGMT levels. (Shibata et al., 2006) MMR is represented 
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by a protein complex dedicated to the repair of biosynthetic errors generated 
during DNA replication. The MMR system recognizes base mismatches and 
insertion–deletion loops, cuts the nucleotide sequence containing the lesion, and 
restores the correct base sequence. Therefore, not only MGMT but also MMR is 
involved in target cell susceptibility to triazenes. However, the system does not 
suppress, but instead promotes the cytotoxic effects of triazenes. In fact, MMR is 
not able to repair the incorrect base pairing determined by treatment with 
triazenes and, according to a predominant hypothesis, it causes reiterated “futile” 
attempts of damage repair leading to the activation of cell cycle arrest and 
apoptosis. BER removes lesions due to cellular metabolism, or to physical or 
chemical agents. BER is able to repair N
7
-methylguanine and N
3
-methyladenine 
determined by treatment with triazenes (Marchesi et al., 2007). Therefore, 
triazene compounds can also kill tumour cells by a N
3
-methyladenine-mediated 
mechanism if BER activity is inhibited by chemical agents (i.e. PARP inhibitors). 
  Temozolomide and Lomeguatrib are known to work best when given in 
combination. For any drug to be approved for usage, it has to undergo various 
clinical trials. Stability studies also have to be performed on them. HPLC is 
majorly used to conduct stability studies on drugs, to evaluate their metabolic by-
products and to check them for toxicity levels. Temozolomide is an approved 
drug and so has been checked for stability earlier, the articles of which have been 
published.  A few by-products like MIT (Kim et al., 2001) were even recognised 
and analysed. There aren’t articles representing the stability indicating studies for 
Patrin-2 available. Articles also haven’t been published to indicate the by-
products of this drug. Designing a stability indicating method for Patrin-2 and 
find out its by-products on degradation and check their toxicity level, and hence 
concluding the feasibility of this drug for treatment of cancer without being 
dangerous to life will be of great interest. Also the by-products acquired when the 
two drugs are used in combination will be an interesting study. 
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1.3 Drug Stability Studies 
Stability testing of drugs requires an accurate analytical method that quantifies 
active pharmaceutical ingredients (API) without interference from degradation 
products, process impurities and other potential impurities. Stability-indicating 
HPLC methods are designed for drugs. Stability-indicating analytical method is 
validated, specific, and quantitative analytical method, which is capable of 
accurately testing API, degradation products, and other components of interest 
without interference. The stability-indicating method is used to detect the changes 
with time in the chemical, physical, or microbiological properties of the drug 
substance and drug product. The quality of a drug product depends on the quality 
of API. The changes in API itself and related impurities have to be examined 
throughout the drug life. An ideal situation is that the API and all the impurities 
can be accurately measured with one method. Nevertheless, secondary validated 
complemented method may also be used when a single method is unattainable to 
examine all of the components at the same time. Stability information is needed 
for regulatory submissions such as IND (Investigational New Drug Application) 
and NDA (New Drug Applications) and to set expiration dates for the API or 
drug product. 
1.3.1 Forced Degradation 
 The forced degradation studies are another very important part of the validation 
of the stability indicating method. In forced degradation studies, samples are 
stored under extreme conditions (acid, base, peroxide, heat, light, humidity etc) in 
order to rapidly screen drug product stabilities. Stability-indicating methods are 
traditionally performed using gradient elution, in order to ensure that degradants 
of various chemical compositions are all detected. 
 
1.3.2 Methods of Degradation: 
In a typical study, relevant stress conditions are light, heat, humidity, hydrolysis 
(acid / base influence) and oxidation or even a combination of described parame-
ters. If it is necessary to form degradation products, the strength of stress 
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conditions can vary due to the chemical structure of the drug substance, the kind 
of drug product, and product specific storage requirements (Alsante, 2011). A 
typical study design should be able to cover different stress conditions using 
different time periods in order to assess the degradation kinetics. 
In our study we are going to use H2O2 to carry out the oxidation. The compound 
will be subjected to UV light, the correlation of a spectrum peak of which will be 
tested at maximum and at beginning and end of a peak. Heat stress or thermal 
stress and acidic stress will also be applied. 
 
1.4 HPLC 
1.4.1 Working of HPLC 
High Performance Liquid Chromatography (HPLC) is one of the most used 
analytical techniques. Chromatographic process is a separation technique 
involving mass-transfer between stationary and mobile phase. HPLC utilises a 
liquid mobile phase to separate the components of a mixture (Lindsay and 
Barnes, 1992). The stationary phase can be a liquid or a solid phase. Reversed 
phase chromatography is commonly used to carry out stability studies. They are 
called reversed phase because the stationary phase is a tightly packed 
hydrophobic material. These components are first dissolved in a solvent, and then 
forced to flow through a chromatographic column under a high pressure. In the 
column, the mixture separates into its components (Skoog and Leary, 1992). The 
amount of resolution is important, and is dependent upon the extent of interaction 
between the solute components and the stationary phase. The stationary phase is 
defined as the immobile packing material in the column. The interaction of the 
solute with mobile and stationary phases can be manipulated through different 
choices of both solvents and stationary phases (Lindsay and Barnes, 1992). As a 
result, HPLC acquires a high degree of versatility not found in other 
chromatographic systems and it has the ability to easily separate a wide variety of 
chemical mixtures. HPLC is a dynamic adsorption process (Snyder, 1996.). 
Analyte molecules, while moving through the porous packing beads, tend to 
interact with the surface adsorption sites as they are competing with the eluent 
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molecules for the adsorption sites. So, the stronger analyte molecules interact 
with the surface. The weaker the eluent interaction, the longer the analyte will be 
retained on the surface (Narola et al., 2010).  
 
 
Figure 1.3 Typical HPLC system. Adapted from Narola et al., 2010 
 
1.4.2 Validation of HPLC 
  Method development involves a series of sample steps; based on what is known 
about the sample, a column and detector are chosen; the sample is dissolved, 
extracted, purified and filtered as required; an eluent survey (isocratic or gradient) 
is run; the type of final separation (isocratic or gradient) is determined from the 
survey; preliminary conditions are determined for the final separation; retention 
efficiency and selectivity are optimized as required for the purpose of the 
separation (quantitative, qualitative or preparation); the method is validated using 
ICH guidelines (Jain, 2013). The validated method and data can then be 
documented. 
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For stability studies, a stability indicating method is vital. This is for separating, 
detecting, and quantitating possible degradants that could be generated during 
storage conditions. The method should be sensitive to the reportable impurity 
levels. There should also be linearity in the results being obtained (Narola et al., 
2010). Aspects such as the repeatability and reproducibility can be assured on the 
validation of the techniques. The following is the significance of all aspects: 
 
Linearity and range: The linearity of a test procedure is its ability (within a 
given range) to produce results that are directly proportional to the concentration 
of analyte in the sample. The range is the interval between the upper and lower 
levels of the analyte that have been determined with precision, accuracy and 
linearity using the method as written. ICH guidelines specify a minimum of five 
concentration levels, along with certain minimum specified ranges. For assay, the 
minimum specified range is 80–120% of the theoretical content of active. 
Acceptability of linearity data is often judged by examining the correlation 
coefficient and y-intercept of the linear regression line for the response versus 
concentration plot. The regression coefficient (r
2
) is .0.998 and is generally 
considered as evidence of acceptable fit of the data to the regression line. The per 
cent relative standard deviation (RSD), intercept and slope should be calculated. 
 
Accuracy: A method is said to be accurate if it gives the correct numerical 
answer for the analyte. The method should be able to determine whether the 
material in question conforms to its specification. However, the exact amount 
present is unknown, which is why a test method is used to estimate the accuracy. 
Furthermore, it is rare that the results of several replicate tests all give the same 
answer, so the mean or average value is taken as the estimate of the accurate 
answer. 
 
Specificity: Developing a separation method for HPLC involves demonstrating 
specificity, which is the ability of the method to accurately measure the analyte 
response in the presence of all potential sample components. The response of the 
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analyte in test mixtures containing the analyte and all potential sample 
components (placebo formulation, synthesis intermediates, excipients, 
degradation products and process impurities) is compared with the response of a 
solution containing only the analyte. 
Precision: Precision means that all measurements of an analyte should be very 
close together. All quantitative results should be of high precision - there should 
be no more than a ±2% variation in the assay system. A useful criterion is the 
relative standard deviation (RSD) or coefficient of variation (CV), which is an 
indication of the imprecision of the system. 
 
Limits of detection and quantitation: The limit of detection (LOD) is defined 
as the lowest concentration of an analyte in a sample that can be detected, not 
quantified. The limit of quantitation (LOQ) is defined as the lowest concentration 
of an analyte in a sample that can be determined with acceptable precision and 
accuracy under the stated operational conditions of the method. 
Robustness: Robustness measures the capacity of an analytical method to remain 
unaffected by small but deliberate variations in method parameters. It also 
provides some indication of the reliability of an analytical method during normal 
usage. Parameters that should be investigated are per cent organic content in the 
mobile phase or gradient ramp; pH of the mobile phase; buffer concentration; 
temperature; and injection volume. These parameters may be evaluated one 
factor at a time or simultaneously as part of a factorial experiment.  
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1.5 Research questions and specific aims 
The main question to be answered by this study is, 
Is it possible to design a validated Stability Indicating Method for Lomeguatrib 
using HPLC? 
Other questions that could arise out of this study are, 
Is it possible to quantify and identify the products formed on degradation of 
Lomeguatrib under different conditions? 
 
1.5.1 The working hypothesis 
A validated Stability Indicating Method can be designed for the analysis of 
Lomeguatrib by subjecting it to accelerated or forced degradation. 
1.5.2 Specific Aims 
1. Design a method where Lomeguatrib is subjected to varied stress conditions 
and thus observe the difference in the degradation pattern. 
2. To observe the drug lability under various stress conditions. 
3. To recognise conditions in which the drugs is stable and thus, design a method 
that can indicate the shelf-life of the drug. 
4. To locate degradation products of Lomeguatrib on the HPLC Chromatogram 
and try and identify them, if possible. 
5. To validate the method designed. 
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CHAPTER 2 
MATERIALS AND METHODS 
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2.1 Materials and Reagents 
The chemicals, reagents and materials used in this study are listed below. They 
were handled and stored as instructed by the suppliers or based on the manuals 
provided with them. Chemicals and reagents were of HPLC grade and suitable for 
analysis. They have been summarised in tabular format and listed alongside is the 
name of their supplier. 
Table 2.1 List of materials and reagents used in this study. 
Chemicals/Materials/Reagents Supplier 
Patrin-2 (Lomeguatrib)  (2gms) Sequoia Research Products 
(SeqChem) 
HPLC grade Acetonitrile 98% Fisher Scientific (UK) 
 
HPLC grade Methanol 99+% Fisher Scientific (UK) 
Hydrogen Peroxide 30% Sigma Aldrich (UK) 
1-Methyl-2-pyrrolidinone; anhydrous, 99.5% 
or n-methylpyrrolidone 
Sigma Aldrich (UK) 
Dimethyl Sulfoxide (DMSO) 99+% Fisher Scientific (UK) 
HPLC grade Water Fisher Scientific (UK) 
Citric acid  ≥99.5% Sigma Aldrich (UK) 
Sodium Dodecyl Sulfate (SDS) ≥99.0% Sigma Aldrich (UK) 
 
Tetrabutylammonium acetate (TBAA) 97% Sigma Aldrich (UK) 
pHmeter buffers Sigma Aldrich (UK) 
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2.2 Laboratory Instruments and Equipment 
The instruments and equipment used in this study are as listed below. Listed 
alongside is the name of the company they were purchased from. 
Table 2.2 List of instruments and equipment used in this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Besides these, glassware like glass bottles with screw cap (1L and 500ml), vials with 
screw cap (2ml, 3ml, 5ml, 10ml), beakers (500ml and 1L) were purchased from 
Fisher Scientific (UK). UV Lamp Reflector chamber and Quartz cuvettes with cover 
from AlphaCure were used for photolysis. Spectrophotometer, incubators and oven 
from Thermo Scientific were used. Glass pipettes,weighing scale, pHmeter, round 
bottomed flasks with the mark of 10ml, 20ml, 50ml, 100ml, 1L and measuring 
cylinders of 50ml, 100ml, 500ml and 1L markings were also from Thermo 
Scientific, UK. Paper labels, cellotape, parafilm, aluminium foil and other stationery 
was obtained from the Maudland Stores. 
 
Instrument/ Equipment 
 
Supplier 
HPLC Pump (Jasco PU-1580)  Jasco (UK) 
HPLC Detector (Jasco UV-970M; 4-λ 
intelligent) 
Jasco (UK) 
HPLC column 1 (Symmetry Shield rp18 5m 
5.6*250mm Column) 
Waters Limited (UK) 
HPLC column 2 (Symmetry300 C18 5m 
4.6*250 Column) 
Waters Limited (UK) 
HPLC column guard (SymmetryShield RP18 
5um 3.9*20 Guard 2pk) 
Waters Limited (UK) 
Water bath (Nuve water bath nb 5) Biotech lab (Bulgaria) 
Magnetic Stirrer (RCT basic) IKA RCT basic  (Germany) 
Gilson Micropipettes Thermo Scientific (UK)  
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2.3 Stock Solution for Patrin-2 
Patrin-2 is not easily soluble in organic or inorganic solvents. So, based on initial 
studies, we tried dissolving it in HPLC grade Acetonitrile and Methanol solution 
prepared in (80:20) ratio. A stock solution of concentration 5mg/dL was 
attempted to be prepared for this study. Patrin-2 was sparsely soluble in this 
combination and had to be stirrer on a magnetic stirrer for at least half an hour. 
Also the peak quality obtained by running this solution was superior and 
symmetrical. 
2.3.1 Selection of solvent to form a stock solution of Patrin-2 
Patrin-2 is known to be readily soluble in DMSO. Hence a solvent with a low 
concentration of DMSO was formed. A solvent with 5% DMSO and 25% 
Acetonitrile was made up in HPLC grade water. Water diluted the concentration 
of both DMSO and Acetonitrile to avoid them from bringing about degradation in 
Patrin-2 as that could have lead to false results when this solution was subject to 
stress. A stock solution of 5mg/dL is to be formed by accurately weighing out 5 
mgs of Patrin-2 powder and solubilising it in 1L of the solvent.  
2.3.2 N-methylpyrrolidone as solvent 
N-methylpyrrolidone is one of the drug components tested to solubilise Patrin-2 
when formulating it’s drug form. We will hence prepare some samples of Patrin-2 
in NMP of 5mg/dL conc. 
 2.3.3 Maximum wavelength selection for Patrin-2     
A small amount from the stock solution was taken to run it on a standardised 
spectrophotometer to determine the maximum wavelength for Patrin-2. It was 
done so by keeping the solvent (5% DMSO and 25% Acetonitrile in HPLC grade 
water) without any Patrin-2 added to it as a blank. 
The wavelength max was determined to be 285nm. A high peak was also seen at 
254nm and 240nm. 
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2.4 HPLC 
2.4.1 HPLC System 
Jasco PU-1580 pump attached to a Jasco UV-970M (4-λ.intelligent) detector and 
a Viglen Pentium-4 was used in the HPLC set-up. AZUR version 5.0.10.0 
software was used for the recording and analysis of the chromatogram of the 
solutions. Figure 2.1 represents a typical HPLC set-up. The set-up includes a  
solvent (mobile phase) which is run through the high pressure pump generating 
and measuring the flow rate of the mobile phase in millilitres per minute. The 
sample to be analysed is introduced in the injector from where it is introduced in 
the mobile phase flowing through the column consisting of chromatographic 
packing material (C18) also termed as the stationary phase. From the column the 
flow is directed to the detector. The components are then analyzed by the 
detector from where the chromatographic image is produced in the computer. 
The chromatogram produced displays the retention time and the peak area of the 
expected compound on the monitor with the help of AZUR 5.0.0. 
 
Figure 2.1 HPLC set-up used for the analysis. 
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The chromatographic experiments were performed at three wavelengths 240nm, 
254nm and 285nm. The flow rate was kept constant at 1mL/min. A mobile phase 
was selected from a previous work (Shervington, L.A. et al, 2005). This was 
prepared by adding 10mM SDS, 10mM TBAA and 25mM citric acid to 35% 
Acetonitrile in HPLC grade Water.  For a litre of this mobile phase, 2.88gms of 
SDS, 4.88gms of citric acid and 3.0273gms of TBAA is weighed and solubilised 
in 350ml of acetonitrile and then water is added to fill it upto the 1L mark. 
 
2.4.2 HPLC column: 
We had selected a reverse phase chromatography system. The columns in this set 
up usually have silica as the main packing material bonded with carbon chains. 
The loner the chains, the more is the retentive capacity. The sample size that can 
be used in a column with C18 packing is twice the size of the sample that can be 
used on the column with C4 packing. We looked for a column that matched our 
needs and gave us a broader range of usage. Symmetry300 column with a column 
guard from Waters’, UK was used for the analysis. This is a reversed-phase C18 
column. This particular one was selected so we could obtain sharp and superior 
peak. 
 
 
2.5 Validation of HPLC        
The HPLC system had to be validated before it could be used to analyse the 
products formed by subjecting the Patrin-2 solution to stress. 
This was done by considering the aspects as per the guidelines described before. 
The following tests were carried out. 
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 2.5.1 Linearity 
To measure the linearity of the system, a stock solution of 5mg/dL was made and 
diluted to 4mg/dL, 3mg/dL, 2mg/dL and 1mg/dL. It was done by adding the stock 
solution and the solvent mix (DMSO, acetonitrile and water mix) in appropriate 
ratios. These samples were then run on the HPLC system as specified earlier. 
Each sample was run twice and a mean of the peak area was recorded. based on 
this, we calculated the slope and the regression co-efficient. The values for these 
have been listed in the results section. 
 2.5.2 Repeatability (Intraday precision study) 
To check the repeatability of the system, the system was injected 5 times with the 
same sample, to check the peak area obtained after every run. 2mg/dL was the 
working concentration. The sample prepared of this concentration was injected 
five times to the system and was let to run till the solution came out of the 
column. The mean of the peak areas obtained after the five runs was taken. The 
peak area values were used to obtained the standard deviation and relative 
standard diviation for this method. 
 2.5.3 Reproducibility 
Reproducibility of the method was checked by preparing five samples of a 
particular concentration of Patrin-2 in a similar manner and running them on the 
system twice. A mean peak area of the two runs of every sample was considered. 
A mean these MPAs was then taken and checked for standard deviation and 
relation standard deviation for this method. 2mg/dL was the working 
concentration for this method. 
2.5.4 Limit of Detection 
Limit of detection was obtained by serially diluting the Patrin-2 solution to its 
half. We started with 1mg/dL and went down until the peak area of Patrin-2 was 
not visible on the chromatogram. Each sample at every concentration was run 
twice. We stopped when the sample at a particular concentration wasn’t 
repeatable. It was found to be at 0.0039mg/dL for Patrin-2. 
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2.5.5 Limit of Quantification  
Limit of quantification was determined by serially diluting the Patrin-2 solution 
to the last concentration which was repeatable. It was found to be 0.0078mg/dL. 
We stopped when the concentration of the solution could not be accurately 
repeated and selected the last repeatable concentration as the limit of 
quantification. We then injected the sample five times to check if it can be 
quantified. We recorded the peak area values each time at this concentration and 
conducted tests for standard deviation and relative standard deviation.  
Chromatographs for these tests have been recorded in the appendix section of this 
thesis. 
After obtaining a validated system for the study, we move on to stability studies. 
 
2.6 Stability Study of Patrin-2   
Stability studies were conducted by subjecting the Patrin-2 solution (5mg/dL) to 
various stress conditions: 
Thermal stress: The stock solution was filled up in vials with screw caps and 60-
70 samples were incubated at 40
o
C, 50
o
C and 80
o
C, keeping it loosely covered 
with screw caps. These were temperatures higher than the human body 
temperature. 80
o
C is a high temperature for storing drugs and is known to degrade 
chemicals when incubated at that high a temperature. This was selected to pass the 
drug through forced degradation. 40
o
C and 50
o
C were comparatively lower 
temperatures, but fast enough to bring about some degradation in the drug. This 
could be compared to check how temperature affects the drug stability, the rate of 
degradation and it’s relation with the temperature and also could help determine a 
shelf life at that particular temperature. Along with these, nitrogen treated samples 
were prepared by sealing them under nitrogen and covering them right after. These 
samples were incubated under these conditions as well. The ones at 40
o
C and 50
o
C 
were analysed every three days, whereas the ones at 80
o
C were analysed on daily 
basis, until the compound degraded completely. 
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Oxidative stress: Two concentrations of H2O2 (30% purity) were prepared, 0.4M 
and 0.8M. These were added to labelled vials and the solution was added in the 
same quantity thus keeping the proportion of H2O2 and stock solution to 1:1. The 
final solution thus obtained is 2.5mg/dL. these samples were incubated at RT, 40
o
C 
and 50
o
C. This being an accelerated reaction, it was analysed in the interval of 
every half hour. 
Photolytic Stress: Photolysis is breakdown of products with strong light 
conditions. Photolytic stress was applied to the stock solution of Patrin-2 (5mg/dL) 
by setting up a UV lamp reflector (330nm) chamber and filling up glass vessel in 
the lamp with the stock solution (180ml). The set up was place in a UV hood and 
was covered with aluminium foil, so as to avoid an contact with the UV radiations. 
The system was carefully turned off every half an hour, and a little amount of the 
solution was taken from the tap below to analyse. 
A few samples were left to be subjected to direct sunlight at the room temperature. 
Acidic and Basic solutions: 0.1M acid and base solutions were obtained. They 
were then added in different apparatus to the stock solution of 5mg/dL in 1:1 ratio 
and were then incubated in vials at RT and 40
o
C. The acid reaction was to be an 
accelerated one, so had to be analysed every 15mins. The base samples were 
analysed everyday initially but was then shifted to once a week analysis. The final 
concentration of these samples is 2.5mg/dL 
Patrin-2 in NMP: 5mg of Patrin-2 was weighed out accurately and solubilised in 
100ml of N-methylpyrrolidone. The samples were then analysed every three days. 
Solid form of the compound was only incubated at the three temperatures. All 
other stress conditions were applied to the liquid form of the compound. The solid 
form, however, was difficult to analyse later, as weighing out small quantity and 
form up solution of a quantity that could be detected within the limits of the 
software to give precise area were both difficult. 
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2.7 Statistical Analysis 
The data from the HPLC was recorded in chromatographs using AZUR version 
5.0. AZUR is a chromatography software developed in Montreal, France. It 
graphically records the column elusions based on the detection in the HPLC 
detector. This gives a graph with peaks when an elute comes out, the size of 
which is based on it’s concentration in the sample injected. The chromatograph 
draws a straight line for the mobile phase elution as the set up is standardised to 
let it run out without giving peaks. 
 The chromatograms were then analysed to obtain the peak areas of Patrin-2 and 
also some of the unidentified by-products so as to compared the rate of 
degradation. This data was recorded in graphic form or tabular form, wherever 
required. The data obtained from the chromatograms was statistically analysed on 
MS Excel and SPSS. Standard tests like standard deviation and average were 
performed. Also the regression coefficient and slope were found wherever 
required.  
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CHAPTER 3 
RESULTS 
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3.1 Validation of HPLC system for Patrin-2 analysis 
As it can be seen in the initial chromatographs in the appendix section, sharp peak 
symmetry was achieved for Patrin-2 using the mobile phase made up by adding 
10mM SDS, 10mM TBAA and 25mM citric acid in a solution of 35% 
Acetonitrile and 65% HPLC grade Water. The pH was maintained at 3.4. The 
validation of the HPLC system for Patrin-2 was done at 285nm (λmax). The 
retention time for Patrin-2 was noted to be approximately 10.7mins. The analysis 
was carried out on the HPLC column Symmetry Shield (Waters, UK) and the 
flow rate of the system was maintained at 1ml/min. For the analysis, Patrin-2 was 
dissolved in a solution of 5% DMSO and 25% Acetonitrile in 70% HPLC grade 
Water to form a stock solution.  
This method was validated by analysing it for linearity, repeatability, 
reproducibility, limit of detection (LOD) and limit of quantification (LOQ). A 
summary of the results is tabulated below. 
 
3.1.1 Linearity 
For checking the linearity, Patrin-2 solutions were prepared in the range of 
1mg/dL to 5mg/dL, keeping the interval 1 (mg %). Duplicates of each 
concentration were made and run on the HPLC system. A mean of the two 
results, which were more or less identical, was considered. 
Table 3.1 Linearity test of Patrin-2. n=2, where n is the number of samples of the 
same concentration analysed and averaged. 
Concentration (mg %) Mean Peak Area 
(MPA) 
5 2015.31 
4 1616.73 
3 1193.065 
2 779.02 
1 393.895 
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A calibration curve was plotted with the mean peak areas against their respective 
concentrations. The range was of concentration was again 1mg/dL to 5mg/dL. 
The regression coefficient (R
2
) value was determined using this plot. 
 
 
Figure 3.1: Calibration curve for Patrin-2 with samples ranging from 
concentrations 1mg/dL to 5 mg/dL against their mean peak area (n=2). The 
regression coefficient (R
2
)= 0.999. 
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3.1.2 Repeatability 
The repeatability of this method was checked using the solution of concentration 
2mg/dL. The standard deviation (SD) of the results was 0.2307 and relative 
standard deviation (RSD) was found to be 0.0296. Since the RSD value was lies 
between the ranges of 0 to 1, the method was determined as repeatable.  
 
Table 3.2 Repeatability test for Patrin-2. Solution of 2mg/dL concentration was 
injected 5 times and a mean of the peak areas was taken to determine the SD and 
RSD values. 
Injection number Peak Area 
1 779.02 
2 778.97 
3 778.56 
4 779.14 
5 779.09 
Mean Peak Area 778.956 
SD 0.230716 
RSD 0.029618 
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3.1.3 Reproducibility 
The reproducibility of this method was checked by making 5 solution of 
concentration 2mg/dL. The standard deviation (SD) of the results was 1.8204 and 
relative standard deviation (RSD ) was found to be 0.2333. Since the RSD value 
lies between the range of 0 to 1, the method was determined as repeatable.  
Table 3.3 Reproducibility test for Patrin-2. Five samples of 2mg/dL 
concentration were made and injected (n=2). A mean of their peak areas was 
taken to determine the SD and RSD values.  
Sample number Peak Area 
1 779.02 
2 781.86 
3 782.01 
4 778.46 
5 778.44 
Mean Peak Area 779.958 
SD 1.8204 
RSD 0.2333 
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3.1.4 Limit of Detection 
The limit of detection for the Patrin-2 solution was found to be 0.003925mg/dL. 
This was obtained by serially diluting the 1mg/dL solution to half its 
concentration, untill the limit of detection was achieved. At this concentration, a 
small peak could be detected, but was not repeatable when it came to the area. 
Thus, the peak detection was qualitative and not quantitative. 
Table 3.4 Limit of detection for Patrin-2 solution. n=2. 
Concentration (mg %) Mean Peak Area (MPA) 
0.5 240.30 
0.25 131.79 
0.125 76.645 
0.0625 38.76 
0.0312 17.54 
0.0156 8.53 
0.0078 5.73 
0.0039 2.94 
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3.1.5 Limit of Quantification 
The limit of quantification for Patrin-2 solution was 0.00785mg/dL. This was 
achieved by serially diluting the 1mg/dL solution of Patrin-2 to half its 
concentration. 0.00785mg/dL was the last concentration , the peak of which could 
be quantified. The analysis of this concentration was repeated 5 times and the SD 
for the results was 0.1247 and the RSD was calculated to be 2.10. The RSD value 
is comparatively low, and so the result was accepted. 
Table 3.5 Limit of quantification for Patrin-2. The sample of the concentration 
0.00785mg/dL was injected 5 times and a mean of the peak areas was calculated 
and the SD and RSD values were thus derived. 
Sample number Peak Area 
1 5.73 
2 5.54 
3 5.81 
4 5.52 
5 5.61 
Mean Peak Area 5.642 
SD 0.1247 
RSD 2.10 
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A summary of the results for every parameter analysed to validate the HPLC 
method is mentioned in the table below. This validated the HPLC system and it 
could be used for further analysis. 
Table 3.6 Summary table for validation of the HPLC method for Patrin-2. 
Parameters Value 
Analytical wavelength 
(nm) 
285 
Stock Solution (Conc.) 5mg/dL 
Linearity Range 
(mg %) 
1 to 5 
Regression equation Y= 406.054x – 14.558 
Regression coefficient 
(R
2
) 
0.999 
RSD (Repeatability) 0.0296 
RSD (Reproducibility) 0.2333 
RSD (LOQ) 2.10 
LOD  0.0039mg/dL 
LOQ  0.0078mg/dL 
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 3.2 Stability indicating method for Patrin-2 
A stock solution of Patrin-2 of 5 mg/dL was prepared in 5% DMSO, 25% 
Acetonitrile and 70% HPLC grade Water. It was incubated in vials or appropriate 
apparatus various conditions as described in the methods. By doing this, it was 
subjected to forced degradation and under all conditions there were degradation 
products formed. In some condition, the degradation was accelerated, while in 
others, the compound was relatively stable and took longer to disintegrate. The 
HPLC analysis was carried out on three different wavelengths, but the results were 
summarised from one (254nm). The stability of Patrin-2 under various conditions 
is summarised for every condition. 
 
 
 3.2.1 Stability of Patrin-2 at 40
o
C, 50
 o
C and 80
 o
C 
Samples were incubated at the three temperatures in vials, sealed loosely from 
above with a plastic screw cap. The nitrogen treated sample vials were incubated at 
the three temperatures too. A standard was made of the same concentration as the 
samples (5mg/dL) and incubated in the refrigerator so that we could accurately get 
the original peak size of Patrin-2 when we run it on the chromatogram before 
running the other samples that have been incubated in the refrigerator. This helps 
in monitoring the extent of degradation each day. The peak area for the standard 
was 1502.02 as can be seen in Appendix Figure 6.32. The samples were then 
analysed on HPLC after a specific time interval. The results have been summarised 
in tables that will follow. 
 
 
 
Table 3.7 The results for the stability of Patrin-2 (5mg %) incubated at 40
o
C, with 
and without treatment with nitrogen. The results are the ones obtained at 254nm. 
(n=2) 
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Sample Type Time 
(days) 
Retention 
Time 
 (min) 
MPA Compound % of Patrin-2 
left after 
degradation.  
Normal 3 3.49 
12.98 
436.16 
1468.89 
UDP 
Patrin-2 
- 
97.79% 
45 3.42 
6.82 
7.28 
7.78 
8.38 
12.38 
517.99 
38.15 
39.55 
30.34 
15.06 
1230.33 
UDP 
UDP 
UDP 
UDP 
UDP 
Patrin-2 
- 
- 
- 
- 
- 
81`.91% 
115 3.42 
6.81 
7.24 
7.72 
8.35 
8.72 
12.30 
672.14 
94.26 
80.97 
74.58 
22.23 
25.71 
950.91 
UDP 
UDP 
UDP 
UDP 
UDP 
UDP 
Patrin-2 
- 
- 
- 
- 
- 
- 
63.30% 
Nitrogen-
treated 
3 3.50 
13.03 
395.70 
1474.66 
UDP 
Patrin-2 
- 
98.17 
45 3.42 
6.80 
7.21 
7.68 
12.25 
427.18 
15.49 
38.35 
22.17 
1310.01 
UDP 
UDP 
UDP 
UDP 
Patrin-2 
- 
- 
- 
- 
87.21% 
115 3.42 
6.81 
7.24 
7.72 
8.36 
8.72 
9.67 
12.32 
371.99 
33.45 
95.46 
53.24 
33.60 
8.99 
13.72 
1147.50 
UDP 
UDP 
UDP 
UDP 
UDP 
UDP 
UDP 
Patrin-2 
- 
- 
- 
- 
- 
- 
- 
76.39% 
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The percentage values in the table corresponding the Patrin-2 concentration are 
taken with comparison to the peak area of Patrin-2 for the standard which was 
1502.02. This means 1502.02 is considered as 100%. It was observed that the 
nitrogen-treated samples degraded slower than the ones not subjected to nitrogen. 
Very little and very slow degradation of Patrin-2 is seen at 40
o
C. 
     
Table 3.8 The results for the stability of Patrin-2 (5mg %) incubated at 50
o
C, with 
and without treatment with nitrogen. The results are the ones obtained at 254nm. 
(n=2) 
Sample Type Time 
(days) 
Retention 
Time (min) 
MPA Compound % of Patrin-2 
left after 
degradation. 
Normal 3 3.50 
6.85 
7.59 
9.98 
13.00 
538.72 
31.28 
34.00 
11.23 
1268.25 
UDP 
UDP 
UDP 
UDP 
Patrin-2 
- 
- 
- 
- 
84.43% 
45 3.42 
6.82 
7.26 
7.75 
8.37 
8.76 
12.36 
14.41 
716.39 
102.50 
117.41 
93.34 
30.75 
39.07 
858.19 
111.29 
UDP 
UDP 
UDP 
UDP 
UDP 
UDP 
Patrin-2 
UDP 
- 
- 
- 
- 
- 
- 
57.02% 
- 
115 3.43 
6.83 
7.29 
7.79 
8.38 
1194.06 
237.44 
235.02 
222.21 
67.64 
UDP 
UDP 
UDP 
UDP 
UDP 
- 
- 
- 
- 
- 
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8.80 
12.40 
14.48 
16.11 
91.98 
325.01 
233.43 
66.13 
UDP 
Patrin-2 
UDP 
UDP 
- 
21.63% 
- 
- 
Nitrogen-
treated 
3 3.50 
6.85 
7.60 
9.99 
12.99 
15.18 
480.07 
26.30 
45.60 
45.59 
1357.05 
30.37 
UDP 
UDP 
UDP 
UDP 
Patrin-2 
UDP 
- 
- 
- 
- 
90.34% 
- 
45 3.42 
6.81 
7.25 
7.74 
8.36 
8.75 
9.68 
12.33 
624.24 
87.65 
140.09 
99.53 
18.87 
27.04 
24.80 
912.28 
UDP 
UDP 
UDP 
UDP 
UDP 
UDP 
UDP 
Patrin-2 
- 
- 
- 
- 
- 
- 
- 
60.73% 
115 3.42 
6.81 
7.25 
7.74 
8.36 
8.76 
12.33 
14.36 
15.98 
950.41 
160.39 
302.63 
229.76 
85.68 
75.56 
449.36 
201.62 
68.02 
UDP 
UDP 
UDP 
UDP 
UDP 
UDP 
Patrin-2 
UDP 
UDP 
- 
- 
- 
- 
- 
- 
29.91% 
- 
- 
   
As can be seen in Table 3.7 and Table 3.8, Patrin-2 disintegrated to a number to 
unidentified products on being subjected to degradation. It degraded faster, the 
more the temperature was increased. At 50
o
C, the degradation seen with or 
without the treatment of nitrogen is more or less the same. The percentage of 
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Patrin-2 left as compared to the original amount is lesser in the 50
o
C incubated 
samples than the 40
o
C incubated samples. 
 
Table 3.9 The results for the stability of Patrin-2 (5mg %) incubated at 80
o
C, with 
and without treatment with nitrogen. The results are the ones obtained at 254nm. 
(n=2) 
Sample Type Time 
(hrs) 
Retention 
Time (min) 
MPA % of Patrin-2 
left after 
degradation. 
Normal 24 12.27 688.78 45.85% 
72 11.61 539.84 35.94% 
168 13.01 17.08 1.13% 
336 12.74 10.46 0.69% 
408 - Undetected/totally 
degraded 
- 
Nitrogen-
treated 
24 12.17 318.97 21.23% 
72 11.95 13.24 0.88% 
168 11.96 10.95 0.72% 
336 - Totally degraded - 
408 - Totally degraded - 
 
At 80
o
C, the samples treated with nitrogen degraded at a very high rate and much 
faster than the ones that weren’t treated with nitrogen. The rate of degradation 
was, in general quite high as compared to the other temperatures.  
The decrease in percentage of the Patrin-2 present after degradation has been 
shown in the last column of every table. It can be observed that the rate at which 
the Patrin-2 is decreasing in the samples is higher at 80
o
C, whereas its lower at 
50
o
C and the lowest at 40
o
C. 
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3.2.2 Oxidation of Patrin-2 using H2O2 
H2O2 was added to the 5mg/dL stock solution of Patrin-2 in (1:1). Thus, the final 
concentration of the solution incubated was 2.5mg/dL. H2O2 was added in two 
different concentrations to different stock solutions, 0.4M and 0.8M. 
The solution prepared in 0.4M H2O2, was incubated at 37
o
C (in a water bath), 40
 
o
C and 50
 o
C, whereas the one prepared in 0.8M H2O2, was incubated at 37
o
C (in 
a water bath) and 40
 o
C. 
There was a high degradation and the compound completely degraded in a few 
hours. The figures below summarise the reaction. 
 
(a.) 
 
(b.) 
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(c.) 
Figure 3.2 Oxidized Patrin-2 at (a.) 240nm, (b.) 254nm, (c.) 285nm. The 
complete degradation of Patrin-2 took 390 mins when 0.4M hydrogen 
peroxide solution of Patrin-2 (2.5mg/dL) was incubated at RT (37
o
C in water 
bath). 
 
This was the slowest oxidation at 390 mins. At other temperatures and for the 
other concentration (0.8M), it took as little as 190 to 240 mins. However, this 
was an accelerated reaction. Patrin-2 level decreased drastically in this 
reaction and the compound probably degraded in a different manner, giving 
different by products on reacting with H2O2. The by-products which increased 
prominently during this procedure were seen at 2.86mins and 3.45mins. There 
were minor quantities of by-products also seen at 6.80mins, 9.78mins and 
14.64mins. The major by-products of this reaction were highly non-polar, as 
this is a reverse phase chromatography. 
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Figure 3.3 Effect of H2O2 (0.4M) on Patrin-2. Patrin-2 gradually degraded in 
the presence of hydrogen peroxide of the lower concentration, when no heat 
was exerted over it. (n=2) 
Peak area of Patrin-2 decreased with time when incubated at RT, in 0.4M 
H2O2. It decerease is linear as can be seen in Figure3.3 and so the decrease in 
peak area or rather concentration of Patrin-2 and increase in the concentration 
of by-products is directly proportional to the time of the reaction. Even though 
H2O2 reaction with the sample is a quick reaction, the one under these 
conditions mentioned above is comparatively lower than the higher incubation 
temperatures and higher H2O2 concentration samples. A summary table can be 
made to compare the rate at which Patrin-2 degraded when subjected to 0.8M 
H2O2 and incubated at RT and 40
 o
C and subjected to 0.4M H2O2 and 
incubated at 40
 o
C and 50
 o
C. Table 3.10 shows a summary of the rate at which 
the compound degraded at approximately the same time intervals. It also 
shows how the concentration of H2O2, the temperature incubation or both 
could accelerate the reaction. 
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Table 3.10 Effect of H2O2 on Patrin-2 solution, when (a) 0.4M of it is added 
to it (1:1 ratio) and incubated at 40
o
C and 50
 o
C, (b) 0.8M of it is added to it 
(1:1 ratio) and incubated at RT and 40
o
C. values derived from the 
chromatogram at 254nm. 
Time 
(mins) 
MPA (n=2) 
0.4M H2O2 0.8M H2O2 
40
o
C 50
o
C RT 40
o
C 
15 647.31 512.16 568.87 451.12 
30 432.86 308.99 337.23 287.61 
60 231.77 182.64 113.53 51.81 
120 86.78 76.08 42.11 - 
180 18.13 - - - 
240 - - - - 
 
 
a.)
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b.)
 
c.)
 
d.)
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Figure : 3.4 The HPLC chromatogram showing (a) effect of 0.4M H2O2 at 50
o
C 
at 180min, (b) effect of 0.4M H2O2 at 40
o
C at 240min, (c.) effect of 0.8M H2O2 at 
40
o
C at 120min and (d) effect of 0.8M H2O2 at 37
o
C at 180min @254nm 
    
3.2.3 Stability of Patrin-2 on exposure to UV light: 
 UV Lamp Reflector Chamber was set-up and 180ml of the 5mg/dL stock 
solution of Patrin-2 was poured in the glass vessel of the chamber. It was 
carefully taken out from the tap at the base of the chamber after a certain interval. 
The results of the reaction are summarised below. 
 
Figure 3.5 Effect of UV light on Patrin-2 solution (5mg/dL) solution after 5 
hours of exposure, as seen on a HPLC chromatogram @254nm. 
The figure 3.5 indicates the presence of non-polar by-products when Patrin-2 
solution is exposed to UV light. By-products are seen at 2.47, 2.82, 3.02and 
6.74mins. There are minor traces seen at 4.24, 4.54, 8.58 and 15.55mins too. 
These are the identified peaks seen on photolysis of Patrin-2. 
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Table 3.11 Gradual degradation of Patrin-2 in its solution form (5mg/dL) when 
exposed to UV light. (Abs. 254nm) n=2. 
Time 
(mins) 
Mean Peak Area (MPA) 
30 802.88 
60 278.19 
90 71.93 
120 33.33 
150 26.57 
180 20.85 
210 14.46 
240 9.54 
270 6.18 
300 4.22 
 
 
Figure 3.6 Graph indicating the rate of degradation of Patrin-2 with increase in 
the time. n=2 for MPA. 
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3.2.4 Stability of Patrin-2 when incubated in acidic and basic solutions: 
Acid: 0.1M H2SO4 was prepared and added to the stock solution of Patrin-2 
(5mg/dL) in the ratio of 1:1 to give a final sample of concentration 2.5mg/dL. 
This was incubated at 40
o
C and RT. Rapid degradation was seen and the end 
results were as follows. 
 
Figure 3.7 Patrin-2 solution in 0.1M H2SO4, (1:1) and was incubated at 40
 o
C. 
Patrin-2 completely degraded in 45mins. (Abs. 254nm)  
 
Figure 3.8 Patrin-2 solution in 0.1M H2SO4, (1:1) and was incubated at RT. 
Patrin-2 completely degraded in 50mins. (Abs. 254nm) 
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Patrin-2 quickly degraded under both conditions when acid of as low as 0.1M 
concentration was added to it. It took just about the same time to degrade 
completely in both the conditions. Similar by-products to those in the reaction of 
the sample with H2O2 were seen during the acid reaction of the sample too. There 
non-polar by-products seen in this reaction. By-products were detected at 2.83, 
3.15, 3.50, 6.81 and 14.48mins. Small traces of by-products were seen at 7.85, 
16.10 and 20.32mins. 
 
Base: 0.1M NaOH was prepared and added to the stock solution of Patrin-2 
(5mg/dL) in 1:1 ratio to give 2.5mg/dL concentration samples. This sample was 
incubated at 40
o
C. The results are as below. 
 
Figure 3.9 HPLC chromatogram at 254nm showing the degradation in Patrin-2 
15 days after the base was added to it. The Patrin-2 peak can be seen at 
12.18mins. 
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Figure 3.10 HPLC chromatogram at 254nm showing the degradation in Patrin-2 
45 days after the base was added to it. The Patrin-2 peak can be seen at 
12.52mins. 
 
As can be clearly seen, Patrin-2 has a better stability towards base as compared to 
acid. The same degradation products were formed every time it was subjected to 
degradation. There were a number of both polar and non-polar by-products to this 
reaction. Even though the quantity of the by-products increased, it was gradual 
and slow and the quantity of Patrin-2 went down slowly. Some by-products that 
were observed eluted out at 2.10, 2.64, 5.40, 6.75, 7.15, 7.53, 8.34, 14.53 and 
15.73mins.  
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3.2.5 Stability of Patrin-2 in N-methylpyrrolidone 
Patrin-2 was dissolved in N-methylpyrrolidone to give samples of 5mg/dL conc. 
These samples were left at RT and at 40
o
C. Figures below show the effect NMP 
had on Patrin-2. 
 
 
 
Figure 3.11 A standard of 5mg/dL conc. of Patrin-2 in NMP. 
 
 
Figure 3.12 HPLC chromatogram of Patrin-2 in NMP (5mg/dL) kept at RT. 
After a month, no degradation products can be seen, but there is a change in the 
peak shape. 
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Figure 3.13 HPLC chromatogram of Patrin-2 in NMP (5mg/dL) kept at 40
o
C. 
After a month, no degradation products can be seen, but there is a change in the 
peak shape. 
 
The change in peak shape suggests of some degradation activity in Patrin-2 when 
dissolved in NMP, but the excipients or the degradation products have about the 
same run time in this particular HPLC system. Also, the peak shapes are wide n 
so it’s hard to distinguish how many different by products have been detected. 
This system does not manage to separate the by-products of Patrin-2 solution and 
N-methylpyrrolidone.  
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CHAPTER 4 
DISCUSSION 
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4.1 Validation of HPLC System 
 Validation of the HPLC system was carried out following standard procedures 
for validation. The system was checked for factors like precision, specificity, 
robustness. To do so, linearity test, repeatability and reproducibility tests, 
determination of LOD and LOQ were done. The results were positive in all case. 
They resembled those obtained in the previous works by Dr Leroy Shervington 
on the similar study of Patrin-2. The regression coefficient of the linearity test 
was calculated to be 0.999 which suggested a strong correlation between the 
concentration and the area. This suggested that the dilutions had been carried out 
with precision, accuracy and was specific too. The Relative Standard Deviation 
(RSD) for repeatability and reproducibility were found to be as low as 0.029 and 
0.233 respectively. This suggested that the protocol was reliable and repeatable. 
Various buffers were made and run on the system before selecting the one that 
was used. The buffer recipe was adopted from a previous work done by 
(Shervington, L.A et al, 2005). HPLC column (Symmetry 300) was ordered from 
Waters Ltd. This particular column was selected for the study based on the fact 
that it gives a superior and sharp peak. This was owed to the packing material in 
the column which was C18 chains bonded to the silica. Longer chains produce 
packing that are more retentive and allow use of larger samples, the maximum 
sample size of column type C18 is roughly twice of that of C4 under similar 
conditions (Skoog et al., 2007). 
Patrin-2 is does not have a good solubility. DMSO is the only listed solvent, that 
Patrin-2 is known to dissolve in. This is not an ideal solvent for stability studies. 
A solvent had to be formulated in a way that the concentration DMSO, if it’s 
required at all, had to be kept low. A mix of DMSO (5%), Acetonitrile (25%) in 
HPLC grade water proved to work efficiently.  
 
4.2 Degradation of Patrin-2 at the three temperatures 
Three temperatures were selected to carry out forced degradation; samples were 
incubated at 40
o
C, 50
o
C and 80
o
C. The 5mg/dL Patrin-2 samples reacted in varied 
manner under all the conditions. 
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The compound tends to degrade very slowly when stored at 40
o
C and analysed. 
The samples treated with nitrogen should a slower degradation as compared to  
samples that aren’t treated with nitrogen. Also, solid samples had been incubated 
and tested for degradation and didn’t display degradation. This shows the 
compound is far more stable at 40
oC and didn’t show signs of degradation for 
about a month after incubation. Little degradation was seen after 45 days of 
incubation. 
The compound got unstable when incubated at 50
o
C. The nitrogen-treated and 
non-treated samples, both showed rapid degradation. This helped in determining 
the degradation products formed. On the HPLC chromatogram acquired by 
running the sample on the validated HPLC system, many degradation products 
peaks were seen at 3.42 min, 6.82min, 7.28min, 7.78min, and 8.38min 
respectively on the chromatogram. These were some common peaks seen in all 
chromatograms acquired of degraded Patrin-2 in different conditions. These were 
observed at all the three working absorbance’s and could be quantified 
comparatively better on the 254nm wavelength. 
The drug showed rapid and accelerated degradation when incubated in the 80
o
C 
oven. The drug degraded completely after 15days of incubation. The rate of 
degradation, in this case, was higher in nitrogen treated samples than the ones that 
weren’t treated with nitrogen. 
Forced degradation was achieved with the photolytic tests. Also, the drugs lability 
to each temperature condition could be checked, and helped us determine that 
Patrin-2 is highly unstable when subjected to photolytic stress. The more the 
thermal stress, the faster the compound degrades.  
4.3 Effect of H2O2 on Patrin-2 
0.4M and 0.8M solution was made out of 30% H2O2 and this was added to the 
5mg/dL stock solution of Patrin-2 in the ratio (1:1). These samples of 2.5mg/dL 
thus formed, were stored in varied temperatures and caused oxidative stress to the 
compound. 
They were accelerated degradations. The samples added with 0.4M H2O2 and 
stored at 50
o
C completely degraded in approximately 180mins. 
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The samples incubated at 40
o
C showed a slight difference with the change in 
concentration of H2O2. The ones in which 0.4M of H2O2 was added, took 
180mins before the compound completely degraded, whereas the ones which 
were formed with 0.8M H2O2 displayed a quicker degradation rate and it was 
120mins before the drug completely degraded. 
At body temperature, however, the rate of degradation was slightly slow. The 
solution made of 0.4M H2O2 degraded completely around 390mins and the one 
made in 0.8M H2O2 degraded completely around 240mins when incubated in a 
37
o
C water bath. This was to maintain the temperature similar to the human body 
temperature. 
The results clearly indicated that the compound is labile to oxidative stress. When 
oxidative stress, combined with thermal stress is applied, the compound’s 
degradation accelerates. 
4.4 Effect of light: UV and direct sunlight 
Exposure to direct sunlight had negligible effect on the 5mg/dL Patrin-2 solution. 
The slight change in the peak shape was probably due to the degradation caused 
by DMSO and acetonitrile present in the solvent, even though in a small, in which 
Patrin-2 was solubilised. Over the time, they could be slowly bringing out the 
degradation. 
The exposure to UV radiation, however gave rise to an accelerated forced 
degradation in the compound. The compound displayed a very high degradation 
rate for the initial one hour. Once the quantity of Patrin-2 decreased tremendously 
and the degradation products started forming, the rate of further degradation of 
Patrin-2 effectively slowed down a bit. The compound was nearly degraded 
completely after 5hours of exposure. 
The drug is clearly labile to photolytic stress. 
The drug is subjected to a high temperature, every time its put through photolytic 
stress, or acid stress, or direct temperature stress. If we can accurately determine 
the temperature during each stability profile, we can determine a rate constant for 
that profile based on the rate of degradation at that temperature. As the 
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temperatures have been recorded during our studies, we can determine the rate 
constant. 
4.5 Effect of pH on Patrin-2 
The compound was incubated in acidic and basic conditions. It was stored in 
0.1M acid in 1:1 ratio and so also with 0.1M base. There was a huge difference is 
the reactions that took place after in both the cases. 
Patrin-2 with acid: Patrin-2 is highly unstable when subjected to acidic stress. The 
acidic samples were incubated at RT and at 40
o
C, both of which degraded 
completely within 45mins of incubation. The acidic stress brings about highly 
accelerated degradation in Patrin-2 and the compound is labile to acidic stress and 
this stress is enough by itself to bring about accelerated degradation.  
Patrin-2 with base: The compound was labile in basic surrounding too. But the 
rate of degradation was very slow as compared to the degradation rate seen on its 
incubation in acid. It showed gradual degradation and took about 45 days before 
it showed considerable degradation in base. 
 
4.6 Patrin-2 in NMP 
N-methylpyrrolidone was one of the solvent used to form Patrin-2 tablets. We, 
therefore, decided to check for the stability of Patrin-2 in this solvent. Patrin-2 
readily solubilised in this solvent, however when it was run on HPLC, it showed 
a wide peak, even on a column that was designed for superior peak quality. After 
incubating the compound in NMP for a month, no degradation product seemed to 
have formed in the solution. However, there was seen a change in the peak shape. 
There was, therefore, a possibility that the compound had formed a degradation 
product or maybe products in this solvent which had the retention time nearly 
similar to that of Patrin-2. The wideness of the peak also makes it unsuitable for 
usage in stability indication. There are, however, chances it could give a superior 
peak on some other HPLC system. This could interestingly be used for further 
HPLC studies and analysis on Patrin-2. 
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CONCLUSION 
A validated stability indicating method was achieved using HPLC. The validation 
of the system was carried out effectively indicating the method to be linear, 
precise, accurate, specific and robust. The stability studies on the drug were 
carried out successfully. The drug when subjected to thermal, photolytic, 
oxidative and acidic stress degraded into many degradation products. In most of 
the cases, the degradation rate was seen to be directly proportional to the amount 
of stress applied. The more the thermal stress was increased by increasing the 
incubation temperature, the faster the degradation took place. The more the 
concentration of H2O2, the faster the drug degraded. This further accelerated with 
the increase in temperature. It however, displayed a uniform rate of degradation 
when acidic stress was applied. Even an increase in temperature didn’t seem to 
affect it further. It showed a very high degradation rate when photolysed using 
UV radiations. However, the rate of degradation dropped after the compound 
level in the solution dropped to a very low amount. The drug was seen to be 
highly unstable in most of the conditions it was subjected to. However, it stayed 
stable at RT without any external stress. Even exposure to sunlight had very little 
effect on it. It gradually degraded in alkaline environment too, making it labile to 
acid and base both. It degraded to a number of degradation products. Since this 
drug is designed for usage in treatment for glioma, and has to work in 
combination with Temozolomide, it is highly recommended to try and identify 
the degradation products. This could be done using a mass spectrometer linked to 
the HPLC unit. Also, studies of Patrin-2 have been carried out in combination 
with temozolomide in the past and the drug is withdrawn from usage because of 
it’s highly unstable nature. Most of the degradation was carried out in the solution 
form, and it can be concluded that Patrin-2 is highly unstable when formed into a 
solution. It’s lability to almost all condition makes it difficult to store it if formed 
into a solution. 
This study could also be used to determine the shelf-life of the compound in the 
drug form.  
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FUTURE PROSPECTS 
 
The study carried out as described above has clearly shown Patrin-2 to be highly 
unstable in solution form. It degraded under all stressful conditions it was 
subjected to, some at a high rate and some at slow. It would be interesting, 
though, to analyse the compound in solid form. It could be subjected to various 
stress conditions (thermal, photolytic etc) and analysed check for it’s lability. The 
drug being difficult to solubilise, it would also be interested to check the effect 
humidity has over the solid form. 
A number of unidentified degradation products were formed on degradation of 
this compound. Not enough work has been done on indentifying these products. 
The study could be taken to it’s next stage by identifying some of these products 
and checking for their toxicity. This can be done by running the solutions on 
chromatographic units linked to a mass spectrometer (LC-MS or GC-MS). 
A similar method could be designed in future, keep similar parameters, if the 
monologue of a compound with similar configuration or properties is to be tested 
for stability and has to be subjected to stress conditions to check it’s lability.  
69 
 
 
 
 
 
 
 
 
REFERENCES 
  
70 
 
Alsante, K.M., Baertschi, S.W., Coutant, M., Marquez, B.L., Sharp, T.R., 
Zelesky,
 
T.C. (2011). 3 - Degradation and Impurity Analysis for Pharmaceutical 
Drug Candidates. Separation Science and Technology, vol. 10, 59-169. 
 
Bindra, D. S., Williams, T. D., & Stella, V. J. (1994). Degradation of O6-
benzylguanine in aqueous polyethylene glycol 400 (PEG 400) solutions: concerns 
with formaldehyde in PEG 400. Pharm Res, 11(7), 1060-1064. 
 
Bobola MS, Emond MJ, Blank A, Meade EH, Kolstoe DD, Berger MS, 
Rostomily RC, Silbergeld DL, Spence AM, & Silber JR (2004). Apurinic 
endonuclease activity in adult gliomas and time to tumor progression after 
alkylating agent-based chemotherapy and after radiotherapy. Clin Cancer Res 10, 
7875-7883.  
 
Bobola MS, Silber JR, Ellenbogen RG, Geyer JR, Blank A, & Goff RD (2005). 
O6-methylguanine-DNA methyltransferase, O6-benzylguanine, and resistance to 
clinical alkylators in pediatric primary brain tumor cell lines. Clin Cancer Res 11, 
2747-2755. 
 
Chang SM, Parney IF, Huang W, Anderson FA, Jr., Asher AL, Bernstein M, 
Lillehei KO, Brem H, Berger MS, & Laws ER (2005). Patterns of care for adults 
with newly diagnosed malignant glioma. JAMA 293, 557-564.  
 
 
Kang, H. I., Konishi, C., Eberle, G., Rajewsky, M. F., Kuroki, T., & Huh, N. H. 
(1992). Highly sensitive, specific detection of O6-methylguanine, O4-
methylthymine, and O4-ethylthymine by the combination of high-performance 
liquid chromatography prefractionation, 32P postlabeling, and 
immunoprecipitation. Cancer Res, 52(19), 5307-5312. 
71 
 
Khan OA, Ranson M, Michael M, Olver I, Levitt NC, Mortimer P, Watson AJ, 
Margison GP, Midgley R, & Middleton MR (2008). A phase II trial of 
lomeguatrib and temozolomide in metastatic colorectal cancer. Br J Cancer 98, 
1614-1618. 
 
Kim, H., Likhari, P., Parker, D., Statkevich, P., Marco, A., Lin, C.-C., et al. 
(2001). High-performance liquid chromatographic analysis and stability of anti-
tumour agent temozolomide in human plasma. Journal of Pharmaceutical and 
Biomedical Analysis, 24(3), 461-468. 
 
Kim, H. K., Lin, C.-c., Parker, D., Veals, J., Lim, J., Likhari, P., et al. (1997). 
High-performance liquid chromatographic determination and stability of 5-(3-
methyltriazen-1-yl)-imidazo-4-carboximide, the biologically active product of the 
antitumour agent temozolomide, in human plasma. Journal of Chromatography 
B: Biomedical Sciences and Applications, 703(1-2), 225-233. 
 
King, D. T., & Stewart, J. T. (1993). HPLC Determination of Dacarbazine, 
Doxorubicin, and Ondansetron Mixture in 5% Dextrose Injection on 
Underivatized Silica with an Aqueous-Organic Mobile Phase. Journal of Liquid 
Chromatography, 16(11), 2309-2323. 
 
Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, 
& Cavenee WK (2002). The WHO classification of tumors of the nervous system. 
J Neuropathol Exp Neurol 61, 215-225. 
 
Lindsay S & Barnes J (1992). High performance liquid chromatography 2nd 
 edition. John wiley & sons,West Sussex, UK 1-5.  
 
72 
 
Lopez, S., Margison, G.P., McElhinney, R.S., Cordeiro, A., McMurry, T.B.H., 
Rozas, B. (2011). Towards more specific O
6
-methylguanine-DNA 
methyltransferase (MGMT) inactivators. Bioorganic & Medicinal Chemistry, 
19(5), 1658-1665. 
 
Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, & 
DePinho RA (2001). Malignant glioma: genetics and biology of a grave matter. 
Genes Dev 15, 1311-1333.  
 
Marchesi, F., Turriziani, M., Tortorelli, G., Avvisati, G., Torino, F., Vecchis, 
L.D. (2007). Triazene compounds: Mechanism of action and related DNA repair 
systems. Pharmacological Research, 56(4), 275-287. 
 
Narola, B., Singh, A. S., Santhakumar, P. R., & Chandrashekhar, T. G. (2010). A 
Validated Stability-indicating Reverse Phase HPLC Assay Method for the 
Determination of Memantine Hydrochloride Drug Substance with UV-Detection 
Using Precolumn Derivatization Technique. Anal Chem Insights, 5, 37-45. 
 
Safgren, S. L., Reid, J. M., Rios, R., & Ames, M. M. (2001). Validated high-
performance liquid chromatographic assay for simultaneous determination of 
dacarbazine and the plasma metabolites 5-(3-hydroxymethyl-3-methyl-1-
triazeno)imidazole-4-carboxamide and 5-(3-methyl-1-triazeno)imidazole-4-
carboxamide. Journal of Chromatography B: Biomedical Sciences and 
Applications, 754(1), 91-96. 
 
Sawyer AJ, Piepmeier JM, & Saltzman WM (2006). New methods for direct 
delivery of chemotherapy for treating brain tumors. Yale J Biol Med 79, 141-152.  
 
73 
 
Shen, F., Decosterd, L. A., Gander, M., Leyvraz, S., Biollaz, J., & Lejeune, F. 
(1995). Determination of temozolomide in human plasma and urine by high-
performance liquid chromatography after solid-phase extraction. Journal of 
Chromatography B: Biomedical Sciences and Applications, 667(2), 291-300. 
 
Shervington LA, Abba M, Hussain B, & Donnelly J (2005). The simultaneous 
separation and determination of five quinolone antibiotics using isocratic 
reversed-phase HPLC: application to stability studies on an ofloxacin tablet 
formulation. J Pharm Biomed Anal 39, 769-775. 
 
Shervington, L.A. & N. Sakhnini (2000). A quantitative and qualitative 
highperformance liquid chromatographic determination of acetaminophen and 
five of its para-substituted derivatives Journal of  Pharmaceutical & Biomedical 
Analysis.24, 43-49. 
 
Shibata, T., Glynn, N., McMurry, T. B., McElhinney, R. S., Margison, G. P., & 
Williams, D. M. (2006). Novel synthesis of O6-alkylguanine containing 
oligodeoxyribonucleotides as substrates for the human DNA repair protein, O6-
methylguanine DNA methyltransferase (MGMT). Nucleic Acids Res, 34(6), 
1884-1891. 
 
Skoog DA and Leary JJ (1992). Principles of instrumental analysis 4th edition. 
Saunder college publishing, Florida, USA,628-669.Skoog DA, Holler FJ, & 
Crouch SR (2007). Principles of instrumental analysis 6
th
 international edition. 
Thomson brooks/cole, Belmont, USA, 816-855.  
 
Snyder, L. R. and Dolan, J.W. (1996). Initial experiments in high-performance 
liquid chromatographic method development I. Use of a starting gradient run. 
Journal of Chromatography A, 721(1), 3-14. 
 
74 
 
Stefan, T. L., Ingalls, S. T., Gerson, S. L., Willson, J. K. V., & Hoppel, C. L. 
(1996). Determination of O6-benzylguanine in human plasma by reversed-phase 
high-performance liquid chromatography. Journal of Chromatography B: 
Biomedical Sciences and Applications, 681(2), 331-338. 
 
Stefan, T. L., Ingalls, S. T., Minkler, P. E., V. Willson, J. K., Gerson, S. L., Spiro, 
T. P., et al. (1997). Simultaneous determination of O6-benzylguanine and 8-oxo-
O6-benzylguanine in human plasma by reversed-phase high-performance liquid 
chromatography. Journal of Chromatography B: Biomedical Sciences and 
Applications, 704(1-2), 289-298. 
 
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, 
Belanger K,Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, 
Ludwin SK, Gorlia T,Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, & 
Mirimanoff RO (2005).  
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N 
Engl J Med 352, 987-996. 
 
Trent S, Kong A, Short SC, Traish D, Ashley S, Dowe A, Hines F, & Brada M 
(2002). Temozolomide as second-line chemotherapy for relapsed gliomas. J 
Neurooncol 57, 247-251.  
 
Turriziani M, Caporaso P, Bonmassar L, Buccisano F, Amadori S, Venditti A,  
Cantonetti M, D'Atri S, & Bonmassar E (2006). O6-(4-bromothenyl)guanine 
(PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases 
the inhibitory activity of temozolomide against human acute leukaemia cells in 
vitro. Pharmacol Res 53, 317-323 
 
75 
 
Verbeek, B., Southgate, T. D., Gilham, D. E., & Margison, G. P. (2008). O6-
Methylguanine-DNA methyltransferase inactivation and chemotherapy. British 
Medical Bulletin, 85(1), 17-33. 
 
Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR,  
Jaaskelainen J, & Ram Z (2003). A phase 3 trial of local chemotherapy with 
biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with 
primary malignant glioma. Neuro Oncol 5, 79-88.  
 
  
76 
 
 
 
 
 
 
 
 
 
APPENDIX 
 
 
  
77 
 
Appendix 1: 
Validation of HPLC system for Patrin-2: 
 
Figure 6.1 HPLC chromatogram for Patrin-2 (5mg/dL) n=2. 
 
 
Figure 6.2 HPLC chromatogram for Patrin-2 (4mg/dL) n=2 
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Figure 6.3 HPLC chromatogram for Patrin-2 (3mg/dL) n=2. 
 
 
Figure 6.4 HPLC chromatogram for Patrin-2 (2mg/dL) n=2 
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Figure 6.5 HPLC chromatogram for Patrin-2 (2mg/dL) n=5. Repeatability. 
 
 
Figure 6.6 HPLC chromatogram for Patrin-2 (2mg/dL) n=5. Reproducibility. 
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Figure 6.7 HPLC chromatogram for Patrin-2 (1mg/dL) n=2 
 
 
 
Figure 6.8 HPLC chromatogram for Patrin-2 (0.5mg/dL) n=2 
 
81 
 
 
Figure 6.9 HPLC chromatogram for Patrin-2 (0.25mg/dL) n=2 
 
 
Figure 6.10 HPLC chromatogram for Patrin-2 (0.125mg/dL) n=2 
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Figure 6.11 HPLC chromatogram for Patrin-2 (0.0625mg/dL) n=2 
 
 
Figure 6.12 HPLC chromatogram for Patrin-2 (0.03125mg/dL) n=2 
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Figure 6.13 HPLC chromatogram for Patrin-2 (0.0156mg/dL) n=2 
 
 
Figure 6.14 HPLC chromatogram for Patrin-2 (0.0078mg/dL) n=2.Limit of 
quantification. 
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Figure 6.15 HPLC chromatogram for Patrin-2 (0.0039mg/dL) n=2. Limit of 
Detection. 
 
 
Appendix 2: 
Formulae for Relative Standard Deviation (RSD): 
RSD =         SD / MPA x 100 
Where, 
SD= Standard Deviation 
MPA= Mean Peak Area. 
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Appendix 3 
HPLC chromatograms for degradation: 
 
Figure 6.16 Degradation at 40
o
C on day 3 (240nm) 
 
 
Figure 6.17 Degradation at 40
o
C on day 3 (254nm) 
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Figure 6.18 Degradation at 40
o
C on day 3 (285nm) 
 
 
Figure 6.19 Degradation at 40
o
C on day 115 (240nm) 
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Figure 6.20 Degradation at 40
o
C on day 115 (254nm) 
 
 
Figure 6.21 Degradation at 40
o
C on day 115 (285nm) 
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Figure 6.22 Degradation at 50
o
C on day 3 (240nm) 
 
 
Figure 6.23 Degradation at 50
o
C on day 3 (254nm) 
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Figure 6.24 Degradation at 50
o
C on day 3 (285nm) 
 
 
Figure 6.25 Degradation at 40
o
C on day 115 (240nm) 
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Figure 6.26 Degradation at 50
o
C on day 115 (254nm) 
 
 
Figure 6.27 Degradation at 50
o
C on day 115 (285nm) 
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Figure 6.28 Total degradation of Patrin-2 @ 80
o
C in 408 hrs (seen at 240nm, 
254nm and 285nm, respectively) 
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 (a.) 
 (b.) 
 (c.) 
Figure 6.29 NMP run by itself with the working mobile phase at (a) 240nm, (b) 254nm 
and (c) 285nm 
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Figure 6.30 Patrin-2 solution (5mg/dL) exposed to direct sunlight at RT. 
Chromatogram for the changes after one month of exposure (in summertime) 
 
 
Figure 6.31 Patrin-2 solution (5mg/dL) exposed to direct sunlight at RT. 
Chromatogram for the changes after two month of exposure (in summertime) 
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Figure 6.32 Patrin-2 solution (5mg/dL) standard solution. Peak Area of Patrin-2 is 
1502.02 
